中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(7)——家族遗传性前列腺癌

2022-01-30 中国抗癌协会家族遗传性肿瘤专业委员会 中国肿瘤临床

前列腺癌是一种具有高度遗传性的癌症,据估计约40%~50%的前列腺癌与遗传因素相关。流行病学和家系研究证实前列腺癌有明显的家族聚集性,在这些家族性前列腺癌中,遗传因素扮演了尤为重要的角色。

中文标题:

中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(7)——家族遗传性前列腺癌

发布日期:

2022-01-30

简要介绍:

前列腺癌是一种具有高度遗传性的癌症,据估计约40%~50%的前列腺癌与遗传因素相关。流行病学和家系研究证实前列腺癌有明显的家族聚集性,在这些家族性前列腺癌中,遗传因素扮演了尤为重要的角色。目前已证实多个DNA损伤修复基因的胚系突变与前列腺癌遗传易感相关。以BRCA1和BRCA2为代表的DNA损伤修复基因是迄今为止认识最充分的前列腺癌易感基因,其他DNA损伤修复基因,如ATM、PALB2、CHEK2以及错配修复基因(MLH1、MSH2、MSH6和PMS2)也被认为与前列腺癌风险升高相关。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(7)——家族遗传性前列腺癌.pdf)] GetToolGuiderByIdResponse(projectId=1, id=998c31c00236ae37, title=中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(7)——家族遗传性前列腺癌, enTitle=, guiderFrom=中国肿瘤临床, authorId=0, author=, summary=前列腺癌是一种具有高度遗传性的癌症,据估计约40%~50%的前列腺癌与遗传因素相关。流行病学和家系研究证实前列腺癌有明显的家族聚集性,在这些家族性前列腺癌中,遗传因素扮演了尤为重要的角色。, cover=https://img.medsci.cn/2022224/1645634073131_5579292.jpg, journalId=0, articlesId=null, associationId=2324, associationName=中国抗癌协会家族遗传性肿瘤专业委员会, associationIntro=中国抗癌协会家族遗传性肿瘤专业委员会, copyright=0, guiderPublishedTime=Sun Jan 30 00:00:00 CST 2022, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">前列腺癌是一种具有高度遗传性的癌症,据估计约40%~50%的前列腺癌与遗传因素相关。流行病学和家系研究证实前列腺癌有明显的家族聚集性,在这些家族性前列腺癌中,遗传因素扮演了尤为重要的角色。目前已证实多个DNA损伤修复基因的胚系突变与前列腺癌遗传易感相关。以BRCA1和BRCA2为代表的DNA损伤修复基因是迄今为止认识最充分的前列腺癌易感基因,其他DNA损伤修复基因,如ATM、PALB2、CHEK2以及错配修复基因(MLH1、MSH2、MSH6和PMS2)也被认为与前列腺癌风险升高相关。&nbsp;</span></p>, tagList=[TagDto(tagId=117298, tagName=泌尿生殖系肿瘤), TagDto(tagId=123525, tagName=家族遗传性前列腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4070, appHits=80, showAppHits=0, pcHits=412, showPcHits=3990, likes=1, shares=22, comments=4, approvalStatus=1, publishedTime=Thu Feb 24 15:31:00 CST 2022, publishedTimeString=2022-01-30, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Feb 24 00:36:02 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 15:32:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(7)——家族遗传性前列腺癌.pdf)])
中国家族遗传性肿瘤临床诊疗专家共识(2021年版)(7)——家族遗传性前列腺癌.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1200698, encodeId=104c120069855, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=木小槿maize, createdTime=Tue Mar 08 22:07:28 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199314, encodeId=35a51199314f6, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=145f35c5m30(暂无昵称), createdTime=Fri Mar 04 10:02:16 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198266, encodeId=de231198266ff, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57596427048, createdName=ms3000000403426725, createdTime=Tue Mar 01 09:07:20 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196981, encodeId=82da11969813f, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Thu Feb 24 20:26:48 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-03-08 木小槿maize

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1200698, encodeId=104c120069855, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=木小槿maize, createdTime=Tue Mar 08 22:07:28 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199314, encodeId=35a51199314f6, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=145f35c5m30(暂无昵称), createdTime=Fri Mar 04 10:02:16 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198266, encodeId=de231198266ff, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57596427048, createdName=ms3000000403426725, createdTime=Tue Mar 01 09:07:20 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196981, encodeId=82da11969813f, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Thu Feb 24 20:26:48 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-03-04 145f35c5m30(暂无昵称)

    谢谢提供

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1200698, encodeId=104c120069855, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=木小槿maize, createdTime=Tue Mar 08 22:07:28 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199314, encodeId=35a51199314f6, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=145f35c5m30(暂无昵称), createdTime=Fri Mar 04 10:02:16 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198266, encodeId=de231198266ff, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57596427048, createdName=ms3000000403426725, createdTime=Tue Mar 01 09:07:20 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196981, encodeId=82da11969813f, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Thu Feb 24 20:26:48 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-03-01 ms3000000403426725

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1200698, encodeId=104c120069855, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=木小槿maize, createdTime=Tue Mar 08 22:07:28 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199314, encodeId=35a51199314f6, content=谢谢提供, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62af5100837, createdName=145f35c5m30(暂无昵称), createdTime=Fri Mar 04 10:02:16 CST 2022, time=2022-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198266, encodeId=de231198266ff, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=57596427048, createdName=ms3000000403426725, createdTime=Tue Mar 01 09:07:20 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1196981, encodeId=82da11969813f, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210511/ddebdec707734c8390a07bd0c1048717/cc11caf5d607430e9f4ca556fed68ab1.jpg, createdBy=2c4d5497888, createdName=梅斯助教, createdTime=Thu Feb 24 20:26:48 CST 2022, time=2022-02-24, status=1, ipAttribution=)]
    2022-02-24 梅斯助教

    谢谢

    0